Voluntary nationwide recall: Famotidine (Fresenius – November)

Nov. 2025Pharmacy Updates

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.

This drug is being recalled because the level of a bacteria component called endotoxin was higher than the acceptable range in one sample. Using a product with elevated endotoxin may cause nonserious reactions such as chills, change in mental status, change in breathing status, fever, increase in body temperature, shivering, and shaking. It may also cause severe reactions such as sepsis and septic shock or may lead to death.

As of Nov. 7, the nonserious reactions mentioned above were reported with one lot. There had been no reports of adverse events related to the second and third lots.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Famotidine or are experiencing any problems that may be related to receiving the product, you should stop using it and talk to your doctor.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Fresenius Kabi USA Quality Assurance at 866-716-2459. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. CST.
  • Visit the FDA website.

Recent Announcements

CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care

Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.
Feb. 2026Education/Webinars

Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions

Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.
Feb. 2026Education/Webinars

February 2026 UPMC for You and UPMC Community HealthChoices formulary update

Pulmicort Flexhaler has a new distributor, Rubicon Holding. National Drug Codes (NDCs) for Pulmicort Flexhaler from Rubicon Holding are not included in the Medicaid Drug Rebate program and are not covered under the Medicaid Prescription Drug Program. Pulmicort Flexhaler NDCs from the previous manufacturer, H2 Pharma, have been discontinued but may be billed/dispensed until supplies are exhausted.
Feb. 2026Pharmacy Updates